Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 1
1983 5
1984 3
1985 10
1986 10
1987 7
1988 11
1989 6
1990 10
1991 6
1992 6
1993 6
1994 10
1995 7
1996 3
1999 5
2000 3
2001 2
2002 4
2003 3
2004 4
2005 1
2006 5
2007 4
2008 1
2009 5
2010 9
2011 15
2012 10
2013 6
2014 8
2015 7
2016 3
2017 3
2018 5
2019 1
2020 4
2021 4
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.
Michallet M, Sobh M, Morisset S, Deloire A, Raffoux E, de Botton S, Caillot D, Chantepie S, Girault S, Berthon C, Bertoli S, Lepretre S, Leguay T, Castaigne S, Marolleau JP, Pautas C, Malfuson JV, Veyn N, Braun T, Gastaud L, Suarez F, Schmidt A, Gressin R, Bonmati C, Celli-Lebras K, El-Hamri M, Ribaud P, Dombret H, Thomas X, Bergeron A. Michallet M, et al. Among authors: castaigne s. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):311-318. doi: 10.1016/j.clml.2021.10.011. Epub 2021 Oct 25. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34895843
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML.
Lambert J, Lambert J, Thomas X, Marceau-Renaut A, Micol JB, Renneville A, Clappier E, Hayette S, Récher C, Raffoux E, Pigneux A, Berthon C, Terré C, Celli-Lebras K, Castaigne S, Boissel N, Rousselot P, Preudhomme C, Dombret H, Duployez N. Lambert J, et al. Among authors: castaigne s. Blood Adv. 2021 Dec 14;5(23):5258-5268. doi: 10.1182/bloodadvances.2021004322. Blood Adv. 2021. PMID: 34625784 Free PMC article. Clinical Trial.
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.
Pautas C, Raffoux E, Lambert J, Legrand O, Chantepie S, Gastaud L, Marolleau JP, Thomas X, Turlure P, Benner RJ, Vandendries E, Gogat K, Dombret H, Castaigne S. Pautas C, et al. Among authors: castaigne s. Bone Marrow Transplant. 2021 Jun;56(6):1474-1477. doi: 10.1038/s41409-020-01207-4. Epub 2021 Feb 9. Bone Marrow Transplant. 2021. PMID: 33564120 Free PMC article. Clinical Trial.
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.
Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S, Boissel N, Lambert J, Dombret H, Preudhomme C, Duployez N. Fenwarth L, et al. Among authors: castaigne s. Int J Mol Sci. 2020 Aug 6;21(16):5626. doi: 10.3390/ijms21165626. Int J Mol Sci. 2020. PMID: 32781546 Free PMC article. Review.
A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis.
Bond J, Krzywon A, Lhermitte L, Roumier C, Roggy A, Belhocine M, Kheirallah AA, Villarese P, Hypolite G, Garnache-Ottou F, Castaigne S, Boissel N, Asnafi V, Preudhomme C, Dombret H, Laurenti E, Macintyre E. Bond J, et al. Among authors: castaigne s. Leukemia. 2021 Mar;35(3):724-736. doi: 10.1038/s41375-020-0965-z. Epub 2020 Jul 13. Leukemia. 2021. PMID: 32655144 Free PMC article.
Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow.
Paubelle E, Zylbersztejn F, Maciel TT, Carvalho C, Mupo A, Cheok M, Lieben L, Sujobert P, Decroocq J, Yokoyama A, Asnafi V, Macintyre E, Tamburini J, Bardet V, Castaigne S, Preudhomme C, Dombret H, Carmeliet G, Bouscary D, Ginzburg YZ, de Thé H, Benhamou M, Monteiro RC, Vassiliou GS, Hermine O, Moura IC. Paubelle E, et al. Among authors: castaigne s. Cell Rep. 2020 Jan 21;30(3):739-754.e4. doi: 10.1016/j.celrep.2019.12.055. Cell Rep. 2020. PMID: 31968250 Free article.
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.
Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, Thomas X, Marceau-Renaut A, Chantepie S, Malfuson JV, Lemasle E, Cheok M, Celli-Lebras K, Guerin E, Terré C, Lambert J, Pautas C, Dombret H, Castaigne S, Preudhomme C, Boissel N. Fournier E, et al. Among authors: castaigne s. Blood. 2020 Feb 20;135(8):542-546. doi: 10.1182/blood.2019003471. Blood. 2020. PMID: 31880804 Free article. Clinical Trial.
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.
Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S. Lambert J, et al. Among authors: castaigne s. Haematologica. 2019 Jan;104(1):113-119. doi: 10.3324/haematol.2018.188888. Epub 2018 Aug 3. Haematologica. 2019. PMID: 30076173 Free PMC article. Clinical Trial.
Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).
Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P. Rahmé R, et al. Among authors: castaigne s. Haematologica. 2018 Nov;103(11):e519-e521. doi: 10.3324/haematol.2018.193151. Epub 2018 May 24. Haematologica. 2018. PMID: 29794147 Free PMC article. Clinical Trial. No abstract available.
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.
Cabannes-Hamy A, Peyrade F, Jardin F, Emile JF, Delwail V, Mounier N, Haioun C, Perrot A, Fitoussi O, Lara D, Delarue R, André M, Offner F, Ghesquières H, Pascal L, Soussain C, Lazarovici J, Schiano JM, Gaulard P, Tilly H, Thieblemont C; LYSA; lymphoma study association. Cabannes-Hamy A, et al. Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23. Cancer Med. 2018. PMID: 29473343 Free PMC article. Clinical Trial.
200 results